Optimal Lidocaine Dosing in Patients with Myocardial Infarction

Publisher Website
Google Scholar
Abstract
A decrease in hepatic clearance and volume of distribution in patients with congestive heart failure frequently leads to toxicity when drugs such as lidocaine are administered. To determine the effect of adjusted dosing of lidocaine in patients with myocardial infarction, 32 patients receiving lidocaine either by a conventional method (control group: 1-2 mg/kg bolus, then 1-4 mg/min) or by an adjusted regimen based on the presence or absence of heart failure [expeirmental group: 1-2 mg/kg bolus; then, class I (no heart failure), 35-88 .mu.g/kg per min; class II (heart failure), 12-35 .mu.g/kg per min] were studied. Plasma lidocaine levels were determined at 2 and 5 h of the infusion by enzyme multiplied immunoassay technique (EMIT) and GLC. Of 33 determinations in the control group, 10 were in the toxic range, i.e., > 6 .mu.g/ml and 4 others were subtherapeutic, i.e., < 2 .mu.g/ml. Of 16 determinations in the experimental group, 13 were in the therapeutic range and none were in the toxic range. Administration of lidocaine by a conventional method may produce diverse plasma levels that may occasionally be in the toxic range. Modified dosing based on cardiac status may result in optimal levels in most patients.

This publication has 1 reference indexed in Scilit: